Skip to main content

Brussels (Belgium) – March 2, 2023

Quantoom Biosciences S.A. (“Quantoom”), a Belgian biotech with the mission to reinvent mRNA production announces today the opening of a brand-new facility in Évry-Courcouronnes (France).

Following the SynHelix acquisition in 2021, Quantoom already had infrastructures in France, part of the Genopole campus, but these were no longer suitable in view of the dazzling development of the NplifyTM product line (DNA production service), whose activities are mainly concentrated in the team France.
The new facilities are 4 times larger than before and can accommodate the increasing number of equipment and collaborators in order to meet the ambitious goals of the company for the upcoming years. Today, Quantoom in France is led by Irina Gbalou and counts 24 collaborators including experts in process innovation, enzyme engineering, bioinformatics, lab automation and bioprocess, as well as support functions such as project managers and supply chain.

Figure 1: Rue du Pelvoux 6-18, 91019 Evry-Courcouronnes

Irina Gbalou, Head of Research at Quantoom commented: “With this new infrastructure, Quantoom will be able to further accelerate the NplifyTM project, which consists in providing high-quality grade synthetic DNA in record time. I’m extremely proud of the amazing work the team in France has done so far and can’t wait to see the positive impact it will have on the company’s goals”.

José Castillo, CEO of Quantoom added: “I am thrilled by this new milestone, as it will have a considerable impact on the overall development of NfinityTM the disruptive RNA production platform we have been developing over the last 18 months. Overall, it also contributes to the mission of Univercells (Quantoom’s parent company) of making biologics available and accessible to all.

About Quantoom Biosciences

Quantoom Biosciences is reinventing mRNA production by developing an RNA Platform (NfinityTM) that encompasses DNA (NplifyTM) and RNA (NtensifyTM) manufacturing and formulation (NcapsulateTM), along with critical reagent supply, from sequence to large scale production. We are a team of scientists, engineers and clinicians committed to solving some of the biggest DNA and RNA production challenges facing vaccines and therapeutics, by delivering greater access and autonomy to mRNA technology. Our facilities are strategically located in Belgium and France, in the heart of Europe, benefiting from an exceptional biotech ecosystem. We are part of Univercells, a global life sciences group that makes biologics available to all.

Disclosure Statement

The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified using forward-looking terminology, including the words “believes”, “estimates,” “anticipates”, “expects”, “intends”, “may”, “will”, “plans”, “continue”, “ongoing”, “potential”, “predict”, “project”, “target”, “seek” or “should”, and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company’s actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Contact details

Quantoom Biosciences S.A.
José Castillo
Chief Executive Officer

BE & FR Media Relations
Cécile Hisette